Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov;30(11):2429-2432.
doi: 10.3201/eid3011.231393.

Prevalence of Pertactin-Deficient Bordetella pertussis Isolates, Slovenia

Alex-Mikael Barkoff, Tamara Kastrin, Katja Seme, Marta Grgič Vitek, Jussi Mertsola, Qiushui He

Prevalence of Pertactin-Deficient Bordetella pertussis Isolates, Slovenia

Alex-Mikael Barkoff et al. Emerg Infect Dis. 2024 Nov.

Abstract

In Slovenia, primary acellular pertussis vaccines (ACVs) containing pertactin (PRN) were mostly used during 1999-2016; ACVs without PRN were introduced in 2017. Among 123 Bordetella pertussis strains collected during 2002-2020, a total of 48 were PRN-deficient; 44 were collected after 2017. Changes to ACVs could increase PRN-deficient B. pertussis and infections.

Keywords: Bordetella pertussis; Slovenia; acellular pertussis vaccine; bacteria; pertactin; respiratory infections.

PubMed Disclaimer

Figures

Figure
Figure
Number of PRN-deficient isolates and frequency of fimbrial serotypes in a study of pertactin-deficient Bordetella pertussis isolates, Slovenia, 2002–2020. Vaccines in yellow boxes are those used for primary vaccination; those in the white box are used for booster vaccination. ACV, acellular pertussis vaccine; ACV PRN, ACV containing pertactin; ACV ∆PRN, ACV without pertactin; Fim, fimbriae; PRN, pertactin.
See this image and copyright information in PMC

References

    1. Hiramatsu Y, Miyaji Y, Otsuka N, Arakawa Y, Shibayama K, Kamachi K. Significant decrease in pertactin-deficient Bordetella pertussis isolates, Japan. Emerg Infect Dis. 2017;23:699–701. 10.3201/eid2304.161575 - DOI - PMC - PubMed
    1. Mir-Cros A, Moreno-Mingorance A, Martín-Gómez MT, Abad R, Bloise I, Campins M, et al. Pertactin-deficient Bordetella pertussis with unusual mechanism of pertactin disruption, Spain, 1986–2018. Emerg Infect Dis. 2022;28:967–76. 10.3201/eid2805.211958 - DOI - PMC - PubMed
    1. Kastrin T, Barkoff AM, Paragi M, Vitek MG, Mertsola J, He Q. High prevalence of currently circulating Bordetella pertussis isolates not producing vaccine antigen pertactin in Slovenia. Clin Microbiol Infect. 2019;25:258–60. 10.1016/j.cmi.2018.10.005 - DOI - PubMed
    1. Barkoff AM, Guiso N, Guillot S, Xing D, Markey K, Berbers G, et al. A rapid ELISA-based method for screening Bordetella pertussis strain production of antigens included in current acellular pertussis vaccines. J Immunol Methods. 2014;408:142–8. 10.1016/j.jim.2014.06.001 - DOI - PubMed
    1. Barkoff AM, Mertsola J, Pierard D, Dalby T, Hoegh SV, Guillot S, et al. Pertactin-deficient Bordetella pertussis isolates: evidence of increased circulation in Europe, 1998 to 2015. Euro Surveill. 2019;24:1700832. 10.2807/1560-7917.ES.2019.24.7.1700832 - DOI - PMC - PubMed

LinkOut - more resources